Bristol-Myers initiated the recalls as a precautionary measure after receiving a customer complaint about a 5 milligram bottle of Eliquis actually containing 2.5 milligram tablets, according to a recall notice from The Food and Drug Administration.
The tablets differ in color, size and markings. The FDA has not received any reports of adverse event associated with the medication error. Atrial fibrillation patients taking a lower-than-prescribed dose of Eliquis would be at an increased risk for stroke, according to the agency.
Bristol-Myers distributed the affected pills to wholesalers and retail pharmacies in February. The drugmaker is working with customers to arrange for the return and replacement of all affected pill bottles, according to the FDA notice.
More articles on supply chain:
Takeda Pharma taps AI platform for drug development
3 things to know about the Senate Health Committee’s drug price hearing
Top pharmacist-recommended health products for 2017
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.